2016
DOI: 10.18632/oncotarget.10523
|View full text |Cite
|
Sign up to set email alerts
|

Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies

Abstract: Standard clinicopathological variables are inadequate for optimal management of prostate cancer patients. While genomic classifiers have improved patient risk classification, the multifocality and heterogeneity of prostate cancer can confound pre-treatment assessment. The objective was to investigate the association of multiparametric (mp)MRI quantitative features with prostate cancer risk gene expression profiles in mpMRI-guided biopsies tissues.Global gene expression profiles were generated from 17 mpMRI-dir… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
80
0
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 94 publications
(81 citation statements)
references
References 53 publications
0
80
0
1
Order By: Relevance
“…Although we did not identify any significant correlations between the mutation profiles and multiparametric MR imaging measures, this may have been a limitation of the sample size because recent studies (35,36) investigating imaging correlates of multiparametric MR imaging and gene expression in prostate cancer show some promise for possible association maps to be constructed. Additionally, although detailed review by a genitourinary pathologist and genitourinary radiologist to ensure concordance of MR imaging and histologic specimens supported spatial concordance of the multiparametric MR imaging description and sequenced tissue, the development of objective, electronic registration of whole mounts with MR imaging (37–39) could assist in colocalizing lesions with greater accuracy, accounting for differences in nonconcordance of the axial axis in the MR versus the whole-mount sections (ie, obliquities between multiparametric MR imaging axial and whole-mount specimen slices).…”
Section: Discussionmentioning
confidence: 62%
“…Although we did not identify any significant correlations between the mutation profiles and multiparametric MR imaging measures, this may have been a limitation of the sample size because recent studies (35,36) investigating imaging correlates of multiparametric MR imaging and gene expression in prostate cancer show some promise for possible association maps to be constructed. Additionally, although detailed review by a genitourinary pathologist and genitourinary radiologist to ensure concordance of MR imaging and histologic specimens supported spatial concordance of the multiparametric MR imaging description and sequenced tissue, the development of objective, electronic registration of whole mounts with MR imaging (37–39) could assist in colocalizing lesions with greater accuracy, accounting for differences in nonconcordance of the axial axis in the MR versus the whole-mount sections (ie, obliquities between multiparametric MR imaging axial and whole-mount specimen slices).…”
Section: Discussionmentioning
confidence: 62%
“…In an analysis of prostate biopsy samples from six patients, a group of investigators from the University of Miami correlated 49 multiparametric MRI features with 69 genes from three commercially available prostate cancer gene signatures, ie, Oncotype DX Genomic Prostate Score, Decipher Prostate Cancer Classifier, and Prolaris Cell Cycle Progression. They separately analyzed regions that were suspicious for harboring tumor as well as regions with normal‐appearing prostatic tissue and reported strong associations of imaging features with the expression of genes associated with immune/inflammatory response, metabolism, and cell and biological adhesion (Fig.…”
Section: Prostatementioning
confidence: 99%
“…As currently no low‐cost genetic testing is readily available, the development of accurate surrogates by means of radiogenomics is an active field of research, with initial promising results. Alternatively, radiogenomics might be used to develop imaging surrogates for specific genetic signatures to predict outcome variables, such as response to therapy or early metastases …”
Section: Introduction To Radiogenomicsmentioning
confidence: 99%
“…There was a strong association of the radiomic features identified with known gene signatures that identify aggressive prostate cancer. [122] This provides evidence that the utility of both biomarker testing with advancements in multiparametric MRI may provide a new wealth of clinical utility for prostate cancer.…”
Section: Other Considerations Of Tissue-based Biomarkersmentioning
confidence: 99%